Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

[1]  A. Nishiyama,et al.  Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. , 2007, Journal of the American Society of Nephrology : JASN.

[2]  Michael A. Weber.  Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. , 2007, Reviews in cardiovascular medicine.

[3]  M. Rudnicki,et al.  Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. , 2007, Kidney international.

[4]  F Boomsma,et al.  Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. , 2006, Kidney international.

[5]  G. Remuzzi,et al.  Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. , 2006, The American journal of pathology.

[6]  G. Becker,et al.  Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[7]  G. Remuzzi,et al.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. , 2006, The Journal of clinical investigation.

[8]  A. Collins,et al.  Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.

[9]  E. Ritz,et al.  Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. , 2005, Kidney international.

[10]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[11]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[12]  K. Iseki,et al.  Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[14]  M. Cavasin,et al.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension , 2004, Journal of hypertension.

[15]  S. Satoh,et al.  The combination of lovastatin and enalapril in a model of progressive renal disease , 1994, Pediatric Nephrology.

[16]  G. Remuzzi,et al.  ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? , 2004, Journal of the American Society of Nephrology : JASN.

[17]  G. Remuzzi,et al.  Proteinuria and phenotypic change of proximal tubular cells. , 2003, Journal of the American Society of Nephrology : JASN.

[18]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[19]  S. Yusuf,et al.  Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  G. Remuzzi,et al.  Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.

[21]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[22]  Koichi Hayashi,et al.  Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy , 2003, Hypertension.

[23]  G. Remuzzi,et al.  How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. , 2002, Journal of the American Society of Nephrology : JASN.

[24]  C. Schmid,et al.  Erratum: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (Annals of Internal Medicine (2001) 135 (73-87)) , 2002 .

[25]  K. Tsuchiya,et al.  Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats , 2002, Hypertension.

[26]  G. Remuzzi,et al.  The renin-angiotensin system in progression, remission and regression of chronic nephropathies. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[27]  Giuseppe Remuzzi,et al.  Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System Inhibition , 2002, Annals of Internal Medicine.

[28]  J. Dutil,et al.  Accelerated congenics for mapping two blood pressure quantitative trait loci on chromosome 10 of Dahl rats , 2002, Journal of hypertension.

[29]  R. Blantz,et al.  Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  B. Roniker,et al.  Eplerenone: a selective aldosterone receptor antagonist (SARA). , 2006, Cardiovascular drug reviews.

[31]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[32]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[33]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[34]  J D Mathews,et al.  The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. , 2001, Kidney international.

[35]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[36]  M. Shichiri,et al.  Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  D. Duprez,et al.  Aldosterone and vascular damage , 2000, Current hypertension reports.

[38]  R. Bain,et al.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  H. Oda,et al.  Recent advances in statins and the kidney. , 1999, Kidney international. Supplement.

[40]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[41]  H. Wedel,et al.  Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[43]  J. Ménard,et al.  Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. , 1995, Circulation.

[44]  W. Keane.  Lipids and the kidney. , 1994, Kidney international.

[45]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[46]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[47]  O. Wiklund,et al.  Cholesterol: a renal risk factor in diabetic nephropathy? , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  D. C. Han,et al.  Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  H. Mulec,et al.  Renal protective effect of enalapril in diabetic nephropathy. , 1992 .

[50]  S. Klahr.  The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[51]  B. Brenner,et al.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.

[52]  W. Border,et al.  Anticoagulants are of little value in the treatment of renal disease. , 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  J. Staessen,et al.  Increase in plasma aldosterone during prolonged captopril treatment. , 1982, The American journal of cardiology.

[54]  C. Chantler,et al.  The long-term prognosis of patients with focal segmental glomerulosclerosis. , 1978, Clinical nephrology.